Skip to main content

Epigenomics and Stanford Collaborate in DNA Methylation Research for Cancer Research

NEW YORK, June 9 (GenomeWeb News) - Epigenomics will collaborate with Stanford University in colorectal cancer research, the Frankfurt, Germany-based company said yesterday.

 

Under the agreement, Epigenomics and the Molecular Imaging Program at Stanford University will work with molecular imaging technologies and DNA methylation markers to determine the potential complementary benefits in early colon cancer diagnosis.

 

Traditional scans have a sensitivity of about 85 percent and a specificity of 71 percent in the initial diagnosis while the DNA methylation marker from Epigenomics has a sensitivity "between 50 and 65 percent" and a specificity of 95 percent, according to Cathy Lofton-Day in a statement for Epigenomics.

 

The study will combine both methods to increase sensitivity and specificity of colorectal cancer detection. Up to 120 patients will be enrolled in the study over a period of several months in a two-arm design. Up to 60 patients with confirmed colorectal cancer will be in one arm and up to 60 with other malignancies will be in the second arm.

 

The study is co-funded by Roche Diagnostics and Epigenomics.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.